ALIA-1758 vs CM383

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

ALIA-1758

Developed by AbbVie

Phase 1 in Alzheimer's Diseasemonoclonal antibody (BBB-crossing)
Weak signal

NCT06406348 · Phase 1 · completed

The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.

No aligned efficacy figure on record for this race.

CM383

Developed by Keymed Biosciences

Phase 1 in Alzheimer's Diseasemonoclonal antibody
Weak signal

NCT06412185 · Phase 1 · status unknown

This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted. Its registered primary outcome on ClinicalTrials.gov is "Adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT06619613 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALIA-1758CM383
CDR-SB, change—Not reported—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change—Not reported—Not reported
MMSE, change—Not reported—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

ALIA-1758
—Not reported
CM383
—Not reported

ADAS-Cog11, change

ALIA-1758
—Not reported
CM383
—Not reported

ADCS-ADL, change

ALIA-1758
—Not reported
CM383
—Not reported

MMSE, change

ALIA-1758
—Not reported
CM383
—Not reported

Amyloid PET, change (centiloids)

ALIA-1758
—Not reported
CM383
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALIA-1758: no structured comparison results are available for Alzheimer's Disease.

CM383: no structured comparison results are available for Alzheimer's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · CM383's landscape